Overview

Phase I Study of Oral DFP-11207 in Solid Tumors

Status:
Completed

Trial end date:
2018-09-13

Target enrollment:

Participant gender:

Summary

This is a first-in-human, open label, single arm, sequential dose escalation and expansion study of oral DFP-11207 in patients with advanced solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Delta-Fly Pharma, Inc.

Treatments:

Antimetabolites, Antineoplastic
DFP-11207